Literature DB >> 15366219

Saline infusion markedly reduces impedance and improves efficacy of pulmonary radiofrequency ablation.

Sivakumar Gananadha1, David Lawson Morris.   

Abstract

Radiofrequency ablation (RFA) is a relatively new technique that has been investigated for the treatment of lung tumors. We evaluated for the first time the in vivo use of saline infusion during radiofrequency ablation of sheep lung. We performed RFA on 5 sheep using open and closed chest RFA and the RITA starburst XL and Xli probes using saline infusion with the Xli probe. The impedance and volume of ablation were compared. A total of 16 ablations were produced, 5 percutaneously and 11 open. The impedance during percutaneous and open RFA without saline infusion was 110 +/- 16.2 and 183.3 +/- 105.8 ohms, respectively. With the saline infusion the impedance was 71.3 +/- 22 ohms and 103.6 +/- 37.5 ohms. The effect of this was significantly larger volume of ablation using the saline infusion during percutaneous RFA (90.6 +/- 23 cm3 vs 10.47 +/- 2.9 cm3, p = 0.01) and open RFA (107.8 +/- 25.8 cm3 vs 24.9 +/- 19.3 cm3, p = 0.0002). Saline infusion during RFA is associated with lower impedance, higher power delivery and larger lesion size.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15366219     DOI: 10.1007/pl00021046

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  10 in total

Review 1.  Principles of and advances in percutaneous ablation.

Authors:  Muneeb Ahmed; Christopher L Brace; Fred T Lee; S Nahum Goldberg
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

2.  Microwaves create larger ablations than radiofrequency when controlled for power in ex vivo tissue.

Authors:  A Andreano; Yu Huang; M Franca Meloni; Fred T Lee; Christopher Brace
Journal:  Med Phys       Date:  2010-06       Impact factor: 4.071

3.  Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model.

Authors:  Christopher L Brace; J Louis Hinshaw; Paul F Laeseke; Lisa A Sampson; Fred T Lee
Journal:  Radiology       Date:  2009-03-31       Impact factor: 11.105

4.  Thermal protection with 5% dextrose solution blanket during radiofrequency ablation.

Authors:  Enn Alexandria Chen; Ziv Neeman; Fred T Lee; Anthony Kam; Brad Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Nov-Dec       Impact factor: 2.740

5.  Temperature isotherms during pulmonary cryoablation and their correlation with the zone of ablation.

Authors:  J Louis Hinshaw; Fred T Lee; Paul F Laeseke; Lisa A Sampson; Christopher Brace
Journal:  J Vasc Interv Radiol       Date:  2010-08-04       Impact factor: 3.464

Review 6.  Thermal ablation of malignant lung tumors.

Authors:  Thomas Schneider; Claus Peter Heussel; Felix J F Herth; Hendrik Dienemann
Journal:  Dtsch Arztebl Int       Date:  2013-05-31       Impact factor: 5.594

7.  Radiofrequency ablation of primary and metastatic lung tumors: preliminary experience with a single center device.

Authors:  D Laganà; G Carrafiello; M Mangini; L Boni; G Dionigi; M C Fusi; L Cinquepalmi; F Rovera; S Cuffari; C Fugazzola
Journal:  Surg Endosc       Date:  2006-07-20       Impact factor: 4.584

Review 8.  Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences?

Authors:  Christopher L Brace
Journal:  Curr Probl Diagn Radiol       Date:  2009 May-Jun

9.  Radiofrequency ablation during continuous saline infusion can extend ablation margins.

Authors:  Toru Ishikawa; Tomoyuki Kubota; Ryoko Horigome; Naruhiro Kimura; Hiroki Honda; Akito Iwanaga; Keiichi Seki; Terasu Honma; Toshiaki Yoshida
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

10.  Anatomically Realistic Simulations of Liver Ablation by Irreversible Electroporation: Impact of Blood Vessels on Ablation Volumes and Undertreatment.

Authors:  Radwan Qasrawi; Louis Silve; Fernando Burdío; Ziad Abdeen; Antoni Ivorra
Journal:  Technol Cancer Res Treat       Date:  2017-01-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.